Related Experiment Video
Updated: Dec 20, 2025
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
[Application of convalescent plasma therapy on novel coronavirus infection]
1Department of Respiratory and Critical Care Medicine, Daping Hospital, Army Medical University, Chongqing 400042, China.
Insights
Convalescent plasma (CP) therapy, using plasma from recovered patients, shows efficacy in treating COVID-19 when specific treatments are unavailable. This approach has historical precedent in combating viral epidemics like SARS.
Area of Science:
- Infectious Diseases
- Immunology
- Hematology
Background:
- Coronavirus Disease 2019 (COVID-19) caused by 2019-nCoV has led to a global outbreak with significant clinical pressure due to severe cases.
- Convalescent plasma (CP) therapy involves infusing plasma from recovered donors into infected individuals, a method with historical success in managing epidemics.
- The absence of specific treatments for COVID-19 prompted the exploration and application of CP therapy.
Purpose of the Study:
- To provide a reference for the clinical application of convalescent plasma therapy in COVID-19.
- To discuss the historical context, underlying mechanisms, and application of CP therapy in viral diseases, including SARS.
Main Methods:
- Review of historical data and literature on convalescent plasma therapy for viral diseases.
- Analysis of the mechanism of action for convalescent plasma in conferring immunity.
- Examination of case studies and clinical observations regarding CP therapy in COVID-19 patients.
Main Results:
- Convalescent plasma therapy has demonstrated some efficacy in treating COVID-19.
- The historical application of CP therapy in viral epidemics like SARS provides a basis for its use in new outbreaks.
- Understanding the mechanism of CP therapy is crucial for optimizing its clinical application.
Conclusions:
- Convalescent plasma therapy is a viable option for managing COVID-19 in the absence of specific treatments.
- Further research and standardized protocols are needed to optimize the efficacy and safety of CP therapy for COVID-19.
- CP therapy represents a valuable tool in the management of viral respiratory illnesses.
Abstract:
Coronavirus Disease 2019(COVID-19) caused by 2019-nCoV was in an outbreak globally. A large number of severe cases lead to strong clinical pressure even treated actively. Convalescent plasma (CP) therapy refers to a therapy infusing plasma from recovered donors into other infected individuals. It has played an important role in conquering variety of epidemics over a century with some limitations. Considering the absence of specific treatments, CP has been used for treating COVID-19 and achieved some efficacies. This article provides a reference for clinical application of CP therapy in COVID-19, by discussing the history, mechanism and application of CP therapy in viral diseases such as SARS.
More Related Videos
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:23Acute Respiratory Failure-IV
01:21Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...